Blogs
- Mostly Supportive, Somewhat Divided: Stakeholders Respond to FDA’s Psychedelics Docket
- Before the Approvals Arrive: Norway, Germany, Switzerland, the UK and Estonia at TAIP Conference 2026
- Ten VA Sites, REMS and Ibogaine’s “Uphill Battle”: Feds Weigh In on Psychedelic Access
- Poacher Turned Gamekeeper: HHS’ Matt Zorn on Ibogaine, Right to Try and the Psychedelics Executive Order
- Podcast: Early Healthcare Forum Takeaways, FDA’s Ibogaine Blueprint, and Compass Talks Pricing
- The Psychedelic Practitioner Issue 7: Preparedness (Systems)
- Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD, Psilocybin Brand Names
- Podcast: Oregon Backtracks on Fee Hike, California Funds Psychedelic Research, DEA Moves to Schedule 5 Tryptamines
- Quarterly Psychedelics Briefing: Q3 2026
- Pα+ Psychedelic Bulletin #232: Q2’26 Psychedelic Lobbying Update; DEA Again Moves to Schedule 5 Tryptamines; Oregon Backpedals Psilocybin Fee Hike
- Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers
- Introducing The Psychedelic News Feed Podcast
- Field Notes #5: ‘Psychedelics Week’ in Washington D.C.
- ‘Move Fast, with Precision’: Notes from ARPA-H’s Ibogaine Workshop
- Pα+ Psychedelic Bulletin #231: Compass Shares 52 Week Follow-Up, Training Grant Recipients; Xylo Enters the Clinic; RFK Jr. Hosts Hubbard
Magazines
- Mostly Supportive, Somewhat Divided: Stakeholders Respond to FDA’s Psychedelics Docket
- Before the Approvals Arrive: Norway, Germany, Switzerland, the UK and Estonia at TAIP Conference 2026
- Ten VA Sites, REMS and Ibogaine’s “Uphill Battle”: Feds Weigh In on Psychedelic Access
- Poacher Turned Gamekeeper: HHS’ Matt Zorn on Ibogaine, Right to Try and the Psychedelics Executive Order
- Podcast: Early Healthcare Forum Takeaways, FDA’s Ibogaine Blueprint, and Compass Talks Pricing
- The Psychedelic Practitioner Issue 7: Preparedness (Systems)
- Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD, Psilocybin Brand Names
- Podcast: Oregon Backtracks on Fee Hike, California Funds Psychedelic Research, DEA Moves to Schedule 5 Tryptamines
- Quarterly Psychedelics Briefing: Q3 2026
- Pα+ Psychedelic Bulletin #232: Q2’26 Psychedelic Lobbying Update; DEA Again Moves to Schedule 5 Tryptamines; Oregon Backpedals Psilocybin Fee Hike
- Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers
- Introducing The Psychedelic News Feed Podcast
- Field Notes #5: ‘Psychedelics Week’ in Washington D.C.
- ‘Move Fast, with Precision’: Notes from ARPA-H’s Ibogaine Workshop
- Pα+ Psychedelic Bulletin #231: Compass Shares 52 Week Follow-Up, Training Grant Recipients; Xylo Enters the Clinic; RFK Jr. Hosts Hubbard
Record Labels
- Mostly Supportive, Somewhat Divided: Stakeholders Respond to FDA’s Psychedelics Docket
- Before the Approvals Arrive: Norway, Germany, Switzerland, the UK and Estonia at TAIP Conference 2026
- Ten VA Sites, REMS and Ibogaine’s “Uphill Battle”: Feds Weigh In on Psychedelic Access
- Poacher Turned Gamekeeper: HHS’ Matt Zorn on Ibogaine, Right to Try and the Psychedelics Executive Order
- Podcast: Early Healthcare Forum Takeaways, FDA’s Ibogaine Blueprint, and Compass Talks Pricing
- The Psychedelic Practitioner Issue 7: Preparedness (Systems)
- Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD, Psilocybin Brand Names
- Podcast: Oregon Backtracks on Fee Hike, California Funds Psychedelic Research, DEA Moves to Schedule 5 Tryptamines
- Quarterly Psychedelics Briefing: Q3 2026
- Pα+ Psychedelic Bulletin #232: Q2’26 Psychedelic Lobbying Update; DEA Again Moves to Schedule 5 Tryptamines; Oregon Backpedals Psilocybin Fee Hike
- Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers
- Introducing The Psychedelic News Feed Podcast
- Field Notes #5: ‘Psychedelics Week’ in Washington D.C.
- ‘Move Fast, with Precision’: Notes from ARPA-H’s Ibogaine Workshop
- Pα+ Psychedelic Bulletin #231: Compass Shares 52 Week Follow-Up, Training Grant Recipients; Xylo Enters the Clinic; RFK Jr. Hosts Hubbard
News stories about record stores
- Mostly Supportive, Somewhat Divided: Stakeholders Respond to FDA’s Psychedelics Docket
- Before the Approvals Arrive: Norway, Germany, Switzerland, the UK and Estonia at TAIP Conference 2026
- Ten VA Sites, REMS and Ibogaine’s “Uphill Battle”: Feds Weigh In on Psychedelic Access
- Poacher Turned Gamekeeper: HHS’ Matt Zorn on Ibogaine, Right to Try and the Psychedelics Executive Order
- Podcast: Early Healthcare Forum Takeaways, FDA’s Ibogaine Blueprint, and Compass Talks Pricing
- The Psychedelic Practitioner Issue 7: Preparedness (Systems)
- Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD, Psilocybin Brand Names
- Podcast: Oregon Backtracks on Fee Hike, California Funds Psychedelic Research, DEA Moves to Schedule 5 Tryptamines
- Quarterly Psychedelics Briefing: Q3 2026
- Pα+ Psychedelic Bulletin #232: Q2’26 Psychedelic Lobbying Update; DEA Again Moves to Schedule 5 Tryptamines; Oregon Backpedals Psilocybin Fee Hike
- Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers
- Introducing The Psychedelic News Feed Podcast
- Field Notes #5: ‘Psychedelics Week’ in Washington D.C.
- ‘Move Fast, with Precision’: Notes from ARPA-H’s Ibogaine Workshop
- Pα+ Psychedelic Bulletin #231: Compass Shares 52 Week Follow-Up, Training Grant Recipients; Xylo Enters the Clinic; RFK Jr. Hosts Hubbard